Poxel SA Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
POXEL SA, a biotech company developing treatments for serious diseases, announces the European Commission grant of orphan drug designation for PXL770 and PXL065 for Adrenoleukodystrophy treatment. The ...